What is the virus that is viral fever of humans and primates and that Triazavirin could have a potential application?
Triazavirin Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has an azoloazine base structure, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis, and is also being investigated for potential application against Lassa fever and Ebola virus disease.
Arbovirus Arbovirus is a term used to refer to any viruses that is transmitted by arthropod vectors. The word "arbovirus" is an acronym (ARthropod-BOrne virus). The word "tibovirus" (TIck-BOrne virus) is sometimes used to more specifically describe viruses transmitted by ticks, a superorder within the arthropods. Arboviruses can affect both animals, including humans, and plants. In humans, symptoms of arbovirus infection generally occur 3–15 days after exposure to the virus and last 3 or 4 days. The most common clinical features of infection are fever, headache, and malaise, but encephalitis and hemorrhagic fever may also occur.